Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Contrast-Induced Acute Kidney Injury
Interventions
DRUG

CRMD-001-Deferiprone

CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days

DRUG

Placebo

3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography

Trial Locations (8)

43214

Ohio Health Research Institute, Columbus

43608

St. Vincent Mercy Medical Center, Toledo

45104

Cardiovascular Catheterization Labs at Fairfield, Fairfield

46290

The Care Group, St. Vincent's Hospital, Indianapolis

48075

Providence Hospital, Southfield

48236

St. John Hospital and Medical Center, Detroit

49770

Cardiac and Vascular Research Center of Northern Michigan, Petoskey

73120

Oklahoma Cardiovascular Research Group, Oklahoma City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CorMedix

INDUSTRY

NCT01146925 - Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury | Biotech Hunter | Biotech Hunter